REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
597.62 USD   +0.54%
07:52aRegeneron Says its EYLEA Injection Supplemental Biologics License Application Has Been Accepted by the US FDA for Review
MT
06:24aREGENERON : FDA to Review Extended Eylea Regimen in Diabetic Retinopathy
DJ
06/27Intellia and regeneron present updated interim data from phase 1 study of crispr-based ntla-2001 for the treatment of transthyretin
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target

05/23/2022 | 09:58am EDT


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
07:52aRegeneron Says its EYLEA Injection Supplemental Biologics License Application Has Been ..
MT
06:24aREGENERON : FDA to Review Extended Eylea Regimen in Diabetic Retinopathy
DJ
06/27Intellia and regeneron present updated interim data from phase 1 study of crispr-based ..
AQ
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24SECTOR UPDATE : Health Care
MT
06/24Intellia Therapeutics, Regeneron Report Positive Data From NTLA-2001 Study to Treat Tra..
MT
06/24Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Po..
CI
06/24Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based ..
AQ
06/24REGENERON PHARMACEUTICALS, INC.(NASD : REGN) added to Russell 1000 Dynamic Index
CI
06/15REGENERON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 756 M - -
Net income 2022 4 039 M - -
Net cash 2022 8 626 M - -
P/E ratio 2022 16,3x
Yield 2022 -
Capitalization 64 046 M 64 046 M -
EV / Sales 2022 4,71x
EV / Sales 2023 4,12x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 597,62 $
Average target price 679,24 $
Spread / Average Target 13,7%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.-5.87%64 046
GILEAD SCIENCES, INC.-14.32%78 031
VERTEX PHARMACEUTICALS25.76%70 632
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979
GENMAB A/S-14.75%20 761